Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immatics N.V.
  6. News
  7. Summary
    IMTX   NL0015285941

IMMATICS N.V.

(IMTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release: Immatics Announces Changes to its Board of Directors

05/26/2021 | 07:01am EDT
 
   Tuebingen, Germany and Houston, Texas, May 26, 2021 -- Immatics N.V. 
https://www.globenewswire.com/Tracker?data=Fr3Dd4AOlxE10vCHLFVceI36SqfQ0QehremllUDKXupQQFuLSvI1F2YzQY-oZP9rbxHEOufgqiNo-C6HYWLXjQ== 
(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company 
active in the discovery and development of T cell-redirecting cancer 
immunotherapies, today announced changes to its Board of Directors. 
Christof Hettich, L.L.D., Managing Partner and founding member of the 
dievini Hopp BioTech holding GmbH & Co. KG, has decided to step down 
from Immatics' Board of Directors. He has been a member of Immatics' 
Board of Directors since 2006. Former Immatics Board member Friedrich 
von Bohlen und Halbach, PhD, Managing Partner and co-founder of dievini 
Hopp BioTech Holding GmbH & Co. KG has been nominated to be his 
successor. The election will take place at Immatics' Annual General 
Meeting on June 17, 2021. 
 
   Peter Chambré, Chairman of Immatics' Board of Directors commented: 
"I would like to thank Christof Hettich on behalf of my fellow Board 
members and the Immatics' management team for his tremendous 
contributions to the company for more than 15 years. He has been 
instrumental in the development of Immatics over this period. We would 
be delighted to welcome Friedrich von Bohlen und Halbach back to our 
Board of Directors." 
 
   Dr. Friedrich von Bohlen und Halbach is Managing Partner and co-founder 
of dievini Hopp BioTech Holding GmbH & Co. KG, the company managing the 
life science activities and investments of Dietmar Hopp, co-founder of 
SAP, and his family. Friedrich von Bohlen und Halbach holds a diploma in 
biochemistry from the University of Zurich and a PhD in neurobiology 
from the Swiss Federal Institute of Technology (ETH) in Zurich. He held 
various positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG 
Chemie AG. In 1997 he founded LION bioscience AG whose CEO he was for 
seven years. He is chairman of the Board of Apogenix AG and Novaliq GmbH, 
and board member of CureVac AG, Heidelberg Pharma AG and Co-Chair of the 
Evaluation Board of the Wyss Translational Center Zurich. Friedrich von 
Bohlen und Halbach is also co-founder and Managing Director of Molecular 
Health GmbH. Friedrich von Bohlen und Halbach has been a member of 
Immatics' Board of Directors from 2006 to 2020. 
 
   - END - 
 
   About Immatics 
 
   Immatics combines the discovery of true targets for cancer 
immunotherapies with the development of the right T cell receptors with 
the goal of enabling a robust and specific T cell response against these 
targets. This deep know-how is the foundation for our pipeline of 
Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships 
with global leaders in the pharmaceutical industry. We are committed to 
delivering the power of T cells and to unlocking new avenues for 
patients in their fight against cancer. 
 
   For regular updates about Immatics, visit www.immatics.com. You can also 
follow us on Twitter 
https://www.globenewswire.com/Tracker?data=00CNroZHoO3pwjd_qfbG1bI2ZbieUa2gJJp5d6BB2YOdqR6McXPdYglToQW_q-PKka9DZ1Aux5Ihr3MGBXdW1w== 
and LinkedIn 
https://www.globenewswire.com/Tracker?data=YgvS3cbKLf7l03_fTbBgzJN1Xu-K_lUHcC3PlAqr7GOPyomQWdN3LqWs6o5n0gbOzH-ATiG-P4dc7l0NiwXrdp7PhIbarHOJyL554wkLxQlRJUZByh-19eCJmfdHd9IC 
. 
 
   For more information, please contact: 
 
 
 
 
For media enquiries              Investor Relations Contact 
Jacob Verghese or Stephanie May  John Graziano 
Trophic Communications           Solebury Trout 
Phone: +49 89 2388 7731          Phone: +1 646-378-2942 
immatics@trophic.eu              jgraziano@soleburytrout.com 
 
 
 
 
 
 
 
 
Immatics N.V.             Investor Relations Contact 
Anja Heuer                Jordan Silverstein 
Corporate Communications  Head of Strategy 
Phone: +49 89 540415-606  Phone: +1 281-810-7545 
media@immatics.com        InvestorRelations@immatics.com 
 
 
 
 
   Attachment 
 
 
   -- PDF Version 
      https://ml-eu.globenewswire.com/Resource/Download/6d8a8e08-4b39-484b-ad83-585ee15f3018 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

May 26, 2021 07:00 ET (11:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
CUREVAC N.V. -3.38% 52.37 Delayed Quote.-33.14%
DJ INDUSTRIAL -0.24% 35058.52 Delayed Quote.14.56%
FRESENIUS MEDICAL CARE AG & CO. KGAA -0.35% 68.46 Delayed Quote.0.73%
FRESENIUS SE & CO. KGAA -0.76% 45.135 Delayed Quote.20.19%
HEIDELBERG PHARMA AG -0.72% 6.9 Delayed Quote.0.14%
IMMATICS N.V. -0.58% 12.05 Delayed Quote.12.33%
NASDAQ COMP. -1.21% 14660.575708 Delayed Quote.15.12%
All news about IMMATICS N.V.
07/15IMMATICS N : Corporate Presentation, July 2021
PU
07/15IMMATICS N : 210701 Immatics Corporate Presentation July final.pdf
PU
07/15IMMATICS N : SVB Leerink Adjusts Immatics NV's Price Target to $27 from $26, Kee..
MT
07/07BIOCOPY : AG and Immatics enter into a collaboration to characterize T cell rece..
PR
07/07Biocopy AG and Immatics Enter into a Collaboration to Characterize T Cell Rec..
CI
06/22IMMATICS N : Annual General Meeting of Shareholders (Form 6-K)
PU
05/26IMMATICS N : PRESS RELEASE (Form 6-K)
PU
05/26PRESS RELEASE : Immatics Announces Changes to its Board of Directors
DJ
05/18IMMATICS N : PRELIMINARY NOTE (Form 6-K)
PU
05/18SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
More news
Financials (USD)
Sales 2021 41,5 M - -
Net income 2021 -107 M - -
Net cash 2021 154 M - -
P/E ratio 2021 -7,10x
Yield 2021 -
Capitalization 758 M 758 M -
EV / Sales 2021 14,5x
Capi. / Sales 2022 17,8x
Nbr of Employees 285
Free-Float 55,4%
Chart IMMATICS N.V.
Duration : Period :
Immatics N.V. Technical Analysis Chart | IMTX | NL0015285941 | MarketScreener
Technical analysis trends IMMATICS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,05 $
Average target price 24,00 $
Spread / Average Target 99,2%
EPS Revisions
Managers and Directors
Harpreet Singh-Jasuja Chief Executive Officer & Managing Director
Arnd Christ Chief Financial Officer
Peter Alan ChambrÚ Chairman-Supervisory Board
Cedrik M. Britten Chief Medical Officer
Steffen Walter Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMATICS N.V.12.33%762
MODERNA, INC.221.50%140 065
LONZA GROUP AG20.60%55 634
IQVIA HOLDINGS INC.38.02%47 396
CELLTRION, INC.-26.60%31 265
SEAGEN INC.-18.34%25 955